Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT TN: nab-Paclitaxel with Carboplatin or Gemcitabine in TNBC
NCT01815242Phase 2Completed
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Jun 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Westdeutsche Studiengruppe. Primary endpoints: Pathological Complete Response at 12 weeks and Pathological Complete Response in Responders vs Non-responders at 12 weeks. Started Jun 2013; status: completed.
02
Drugs
paclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01815242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815242.